Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azenosertib - Zentalis Pharmaceuticals

Next Previous
Drug Profile

Azenosertib - Zentalis Pharmaceuticals

Alternative Names: KP-2638; ZN-c3

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zentalis Pharmaceuticals
  • Developer GSK; K-Group Beta; Zentalis Pharmaceuticals; Zentera Therapeutics
  • Class Amines; Antineoplastics; Cyclopentanes; Piperazines; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Solid tumours; Uterine cancer
  • Phase I/II Acute myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
  • Phase I Breast cancer

Most Recent Events

  • 06 Aug 2025 Zentalis Pharmaceuticals announces intention to submit NDA to US FDA for Solid tumour
  • 09 Jul 2025 K-Group Alpha, a subsidiary of Zentalis terminates a phase I/II trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in in US, Australia, Germany, Hungary, Italy, Poland, Spain due to due to change in therapeutic landscape (NCT05743036)
  • 30 May 2025 Efficacy and adverse events data from a phase I trial in Colorectal cancer presented at 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top